Status:
COMPLETED
Memantine Augmentation in Obsessive-Compulsive Disorder
Lead Sponsor:
Stanford University
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).
Detailed Description
The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication....
Eligibility Criteria
Inclusion
- at least 18 years of age
- suffering from OCD
- Y-BOCS score of 18 or greater
- taking a therapeutic dose of an anti-OCD medication specified in the protocol
Exclusion
- diagnosed with a mental disorder other than OCD
- taking tiagabine or pregabalin
- having had a previous trial of memantine
- receiving therapy for OCD
- substance abuse in the last 6 months
- personality disorders sufficiently severe to interfere with study participation
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00264238
Start Date
January 1 2006
End Date
June 1 2008
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305